OTCPK:BOIR.F

Stock Analysis Report

Executive Summary

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

Snowflake

Fundamentals

6 star dividend payer with flawless balance sheet.


Similar Companies

Share Price & News

How has Boiron's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

BOIR.F

0.06%

US Pharmaceuticals

0.5%

US Market


1 Year Return

n/a

BOIR.F

-7.8%

US Pharmaceuticals

6.8%

US Market

Return vs Industry: Insufficient data to determine how BOIR.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BOIR.F performed against the US Market.


Shareholder returns

BOIR.FIndustryMarket
7 Day0%0.06%0.5%
30 Day0%-1.7%-0.8%
90 Dayn/a-1.3%-0.9%
1 Yearn/a-5.5%-7.8%9.2%6.8%
3 Yearn/a18.4%10.1%45.6%36.2%
5 Year-57.1%-57.1%22.2%9.3%63.2%45.4%

Price Volatility Vs. Market

How volatile is Boiron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Boiron undervalued compared to its fair value and its price relative to the market?

32.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BOIR.F ($36) is trading below our estimate of fair value ($53.63)

Significantly Below Fair Value: BOIR.F is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: BOIR.F is good value based on its PE Ratio (15.6x) compared to the Pharmaceuticals industry average (16x).

PE vs Market: BOIR.F is good value based on its PE Ratio (15.6x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

PEG Ratio: BOIR.F is poor value based on its PEG Ratio (72.2x)


Price to Book Ratio

PB vs Industry: BOIR.F is good value based on its PB Ratio (1.2x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Boiron forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

0.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOIR.F's forecast earnings growth (0.2% per year) is below the savings rate (2.7%).

Earnings vs Market: BOIR.F's earnings (0.2% per year) are forecast to grow slower than the US market (14.6% per year).

High Growth Earnings: BOIR.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: BOIR.F's revenue is expected to decline over the next 3 years (-2.3% per year).

High Growth Revenue: BOIR.F's revenue is forecast to decline over the next 3 years (-2.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BOIR.F's Return on Equity is forecast to be low in 3 years time (7.5%).


Next Steps

Past Performance

How has Boiron performed over the past 5 years?

-8.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BOIR.F's earnings have declined by -8.8% per year over the past 5 years.

Accelerating Growth: BOIR.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BOIR.F had negative earnings growth (-52.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (24.3%).


Return on Equity

High ROE: BOIR.F's Return on Equity (7.8%) is considered low.


Return on Assets

ROA vs Industry: BOIR.F's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: BOIR.F's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Boiron's financial position?


Financial Position Analysis

Short Term Liabilities: BOIR.F's short term assets (€368.9M) exceeds its short term liabilities (€141.2M)

Long Term Liabilities: BOIR.F's short term assets (368.9M) exceeds its long term liabilities (129.9M)


Debt to Equity History and Analysis

Debt Level: BOIR.F's debt to equity ratio (1.8%) is considered satisfactory

Reducing Debt: BOIR.F's debt to equity ratio has reduced from 2.3% to 1.8% over the past 5 years.

Debt Coverage: BOIR.F's debt is well covered by operating cash flow (826.7%).

Interest Coverage: BOIR.F earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: BOIR.F has a high level of physical assets or inventory.

Debt Coverage by Assets: BOIR.F's debt is covered by short term assets (assets are 44.991460x debt).


Next Steps

Dividend

What is Boiron's current dividend yield, its reliability and sustainability?

4.58%

Current Dividend Yield


Dividend Yield vs Market

company4.6%marketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Years3.6%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: BOIR.F's dividend (4.58%) is higher than the bottom 25% of dividend payers in the US market (1.45%).

High Dividend: BOIR.F's dividend (4.58%) is in the top 25% of dividend payers in the US market (3.73%)

Stable Dividend: BOIR.F's dividends per share have been stable in the past 10 years.

Growing Dividend: BOIR.F's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (71.6%), BOIR.F's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BOIR.F's dividends in 3 years are forecast to be well covered by earnings (47.9% payout ratio).


Next Steps

Management

What is the CEO of Boiron's salary, the management and board of directors tenure and is there insider trading?

6.0yrs

Average management tenure


CEO

Valérie Lorentz-Poinsot (50yo)

0.8yrs

Tenure

€821,581

Compensation

Ms. Valerie Lorentz-Poinsot serves as General Manager and Director of Development of Boiron SA and served as its Deputy General Manager since July 01, 2011. Ms. Lorentz-Poinsot has been an Executive Direct ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Valérie's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Valérie's compensation has been consistent with company performance over the past year.


Management Age and Tenure

6.0yrs

Average Tenure

61yo

Average Age

Experienced Management: BOIR.F's management team is seasoned and experienced (6 years average tenure).


Board Age and Tenure

16.9yrs

Average Tenure

72yo

Average Age

Experienced Board: BOIR.F's board of directors are seasoned and experienced ( 16.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Christian Boiron (71yo)

    Director

    • Tenure: 45.8yrs
    • Compensation: €925.70k
  • Bruno Grange (66yo)

    International Controller & Director

    • Tenure: 17.4yrs
    • Compensation: €16.22k
  • Fabrice Rey

    Group Treasurer

    • Tenure: 17.9yrs
  • Valérie Lorentz-Poinsot (50yo)

    General Manager & Executive Director

    • Tenure: 0.8yrs
    • Compensation: €821.58k
  • Jean-Christophe Bayssat (56yo)

    Deputy GM

    • Tenure: 3.8yrs
    • Compensation: €1.18m

Board Members

  • Michel Bouissou (77yo)

    Independent Director

    • Tenure: 9.4yrs
    • Compensation: €45.63k
  • Christian Boiron (71yo)

    Director

    • Tenure: 45.8yrs
    • Compensation: €925.70k
  • Bruno Grange (66yo)

    International Controller & Director

    • Tenure: 17.4yrs
    • Compensation: €16.22k
  • Thierry Boiron (58yo)

    Chairman of the Board of Directors

    • Tenure: 8.3yrs
    • Compensation: €291.42k
  • Jean-Pierre Boyer (73yo)

    Director

    • Tenure: 19.4yrs
    • Compensation: €31.77k
  • Michèle Boiron (74yo)

    Director

    • Tenure: 23.1yrs
    • Compensation: €119.46k
  • Jacky Abécassis (77yo)

    Director

    • Tenure: 32.4yrs
    • Compensation: €13.03k
  • Christine Boyer-Boiron (75yo)

    Director

    • Tenure: 16.4yrs
    • Compensation: €13.03k
  • Stéphanie Chesnot (47yo)

    Director

    • Tenure: 9.6yrs
    • Compensation: €31.77k
  • Valérie Lorentz-Poinsot (50yo)

    General Manager & Executive Director

    • Tenure: 0.8yrs
    • Compensation: €821.58k

Company Information

Boiron SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Boiron SA
  • Ticker: BOIR.F
  • Exchange: OTCPK
  • Founded: 1932
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €554.238m
  • Listing Market Cap: €617.398m
  • Shares outstanding: 17.51m
  • Website: https://www.boiron.com

Number of Employees


Location

  • Boiron SA
  • 2, avenue de l’Ouest Lyonnais
  • Messimy
  • Rhône-Alpes
  • 69510
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOIR.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
BOIENXTPA (Euronext Paris)YesOrdinary SharesFREURJan 1992
BONDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
0DTFLSE (London Stock Exchange)YesOrdinary SharesGBEURJan 1992
BOIPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJan 1992

Biography

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded home ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 23:49
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.